Francisco Hernandez-Ilizaliturri, MD

Francisco Hernandez-Ilizaliturri, MD

Roswell Park Cancer Institute
Associate Professor, Department of Medicine
Assistant Professor, Department of Immunology
Areas of Expertise: 
Lymphoma
Multiple myeloma
Chronic lymphocytic leukemia
Special Interests: 
Mechanisms associated with resistance to monoclonal antibodies in lymphoma patients
Developing new strategies to enhance the activity of therapies such as rituximab and other monoclonal antibodies
Board Certification: 
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowship: 
Roswell Park Cancer Institute, Buffalo, NY
Residency: 
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Education and Training: 
MD - InstitutoTecnologico y de Estudio Superiores de Monterrey, Monterrey, Mexico
Active Clinical Trials
Publications
  • Hoppe RT, Advani RH, Ai WYZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H.Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 105:589-597
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British journal of haematology 2012;1564:490-498
  • Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical cancer research 2012;184:1039-1050
  • Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best practice and research. Clinical haematology 2012; 252:185-190
  • Sher T, Lee K, Iancu D, Masood A, Jamshed S, Lawrence W, Soniwala S, Sood R, Hong F, Hernandez-Ilizaliturri FJ, Czuczman MS, Wilding G, Tan W, Wood M, Manfredi D, Miller KC, Ailawadhi S, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology2011; 1541:104-110
  • Wierda WG, Russell CA, Nielsen TG, Gupta I, Chan G, Chang CN, Gorczyca M, Padmanabhan S,Hernandez-Ilizaliturri FJ, Griniute R, Hess G, Smolej L, Mayer J, Stilgenbauer S, Griskevicius L, Durig J, Kipps TJ, on behalf of the 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 11724:6450-6458
  • Vaidyanathan G, Ngamphaiboon N, Hernandez-Ilizaliturri FJ. Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. Annals of hematology 2011; 908:955-962
  • Brem EA, Czuczman MS, Fetterly G, Gibbs JF, Deeb G, Hoskin P, Mavis C, Knight J, Campagna R, Iqbal A, Gu J, Riaz W, Bhat S, Olejniczak SH, Tsai PC, Khubchandani S, Thudium K, Hernandez-Ilizaliturri FJ.Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.British journal of haematology 2011; 1535:599-611
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, MacOn WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 11722:5058-5066
  • Hoppe RT, Advani RH, Ai WYZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J. Hodgkin lymphoma.Journal of the National Comprehensive Cancer Network : JNCCN 2011; 99:1020-1058
  • Castillo JJ, Ribera J-M, Pantanowitz L, Montoto S, Horwitz SM, Hernandez-Ilizaliturri F, Diez-Martin JL, Cwynarski K, Collins JA, Bower M, Bibas M, Beltran BE, Vose JM. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. American journal of hematology 2011;863:256-261
  • Batoo SA, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of lymphoid malignancies. Therapeutic advances in hematology 2011; 21:45-53
  • Chanan-Khan A, Zeldis JB, Wallace PK, Czuczman MS, Hernandez-Illatazurri F, Miller A, Padmanabhan S, Lawrence D, Miller KC, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011; 11710:2127-2135
  • Chavez J, Czuczman MS, Hernandez-Ilizaliturri FJ. Biology and management of diffuse large B-cell lymphoma. Contemporary oncology 2010; 21:28-38
  • Ngamphaiboon N, Pukiat S, Kandimalla Y, Hernandez-Ilizaliturri FJ, Rooney JJ. Diffuse large B-cell lymphoma presenting as pancoast tumor. Journal of clinical oncology 2010; 2816:e254-e256
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Gibbs J, Clements JL, Mavis C, Riaz W, Bangia N, Belicha-Villanueva A, Blickwedehl J, Czuczman MS. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 2010; 11625:5605-5614
  • Sher T, Lee K, Block AW, Wood MT, Sood R, Bilgrami SA, Lawrence W, Miller A, Czuczman MS,Hernandez-Ilizaliturri F, Whitworth A, Lawrence D, Miller KC, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and lymphoma2010; 511:85-88
  • Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leukemia and lymphoma 2010; 51Suppl. 1:1-10
  • Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic research 2010; 461-3:192-205
  • Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current opinion in investigational drugs (London, England : 2000) 2009; 106:579-587
  • Gerber H-P, Benjamin D, Carter PJ, McDonagh CF, Hernandez-Ilizaliturri FJ, Hayes B, Okeley N, Alley SC, McCormick R, Miyamoto J, Morris-Tilden C, Stone I, Kung-Sutherland M, Grewal IS. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009; 11318:4352-4361
  • Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Francisco JH-I, Hansen HJ, Chang C-H.Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 1135:1062-1070
  • Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park, N.Y.) 2009; 236:546-553
  • Hernandez-Ilizaliturri FJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park, N.Y.) 2009; 237:610-615
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical cancer research 2008; 145:1550-1560
  • Hoppe RT, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, Kaminski MS, Hudson MM, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, National Comprehensive Cancer Network. Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 66:594-622
  • Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS.Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British journal of haematology 2008; 1401:36-45
  • Benekli M, McCarthy PL Jr, Padmanabhan S, Battiwalla M, Bambach B, Hernandez-Ilizaliturri F, Czuczman MS, Younis T, Smiley SL, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone marrow transplantation 2008;417:613-619
  • Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma.Clinical lymphoma and myeloma 2008; 85:277-282
  • Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clinical cancer research 2007; 1315 Pt 1:4556-4564
  • Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia and lymphoma 2007; 4812:2424-2436